Aldeyra Therapeutics Newsroom

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

Zacks Nov 19 22:35

FDA accepts aldeyra therapeutics (ALDX.US) potential "first-in-class" dry eye disease therapy for marketing application

aldeyra therapeutics (ALDX.US) announced that the USA FDA has accepted its resubmitted New Drug Application (NDA) for reproxalap, an innovative ophthalmic drug for treating dry eye disease.

Zhitong FinanceNov 19 20:33

BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $11

Futu NewsNov 19 16:36 · Ratings

Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA

MT NewswiresNov 18 21:01

Market-Moving News for November 18th

BenzingaNov 18 20:27

Express News | Aldeyra Therapeutics: Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co if Option Is Exercised

BreakingsNov 18 20:07

Express News | Aldeyra Therapeutics Inc - Pdufa Date Set for April 2, 2025

BreakingsNov 18 20:00

Express News | Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands Abbvie Option Agreement

BreakingsNov 18 20:00

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Yahoo FinanceNov 14 20:00

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Simply Wall StNov 14 18:12

H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10

Futu NewsNov 8 20:35 · Ratings

Aldeyra Therapeutics' Reproxalap: Promising Pipeline and Strategic Partnerships Justify Buy Rating

TipRanksNov 8 19:56 · Ratings

Aldeyra Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 8 05:04 · Announcements

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium During the OSN New York Retina 2024 Meeting

BusinesswireOct 31 19:00

Oppenheimer Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Raises Target Price to $12

Futu NewsOct 4 20:33 · Ratings

Laidlaw Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $11

Futu NewsOct 4 06:32 · Ratings

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment

WSJOct 3 20:27

Express News | Aldeyra Therapeutics Inc - FDA Review of Nda Resubmission Expected Within 6 Months

BreakingsOct 3 19:01

Express News | Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

BreakingsOct 3 19:00

Express News | Aldeyra Therapeutics: Amendment Extends Expiration to April 1, 2026

BreakingsOct 3 04:14